Concepedia

Publication | Open Access

Diroximel fumarate (DRF) in patients with relapsing–remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study

DOIFull Paper Access

62

Citations

15

References

2019

Year

Robert T. Naismith, Jerry S. Wolinsky, Annette Wundes, Christopher LaGanke, Douglas L. Arnold, Dragana Obradović, Mark S. Freedman, Mark Gudesblatt, Tjalf Ziemssen, Boris Kandinov,
Multiple Sclerosis Journal

Abstract

Interim data from EVOLVE-MS-1 suggest DRF is a well-tolerated treatment with a favorable safety/efficacy profile for patients with RRMS.

References

YearCitations

Page 1